VEGFA and capillary leak syndrome: Bevacizumab has exhibited unanticipated efficacy in select cases of CLS (2, 11); however, a notable proportion of patients remains unresponsive despite elevated plasma VEGF levels (1, 5), in contrast to responders who generally exhibit normal VEGF levels.